Cost‐effectiveness of respiratory syncytial virus prophylaxis with palivizumab

200643 citationsJournal Article

Authors

Palivizumab was not cost-effective in the prophylaxis of RSV in the high-risk group of infants tested here.

Good health and well-being

Published in: Journal of Paediatrics and Child Health

Volume 42, Issue 5, pp. 253-258

Field-Weighted Citation Impact: 3.15